BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel MC, Chesnokov A, Jones J, Mishin VP, De La Cruz JA, Nguyen HT, Zanders N, Wentworth DE, Davis TC, Gubareva LV. Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir. Antiviral Res 2021;188:105035. [PMID: 33581212 DOI: 10.1016/j.antiviral.2021.105035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Patel MC, Flanigan D, Feng C, Chesnokov A, Nguyen HT, Elal AA, Steel J, Kondor RJ, Wentworth DE, Gubareva LV, Mishin VP. An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance. Antiviral Research 2022;208:105457. [DOI: 10.1016/j.antiviral.2022.105457] [Reference Citation Analysis]
2 Peng S, Wang H, Wang Z, Wang Q. Progression of Antiviral Agents Targeting Viral Polymerases. Molecules 2022;27:7370. [DOI: 10.3390/molecules27217370] [Reference Citation Analysis]
3 Liao H, Li Y, Yu L, Wu Z, Yang J, Zhu Q. Design, synthesis and structure-activity relationship of dihydrobenzoquinolines as novel inhibitors against influenza A virus. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114799] [Reference Citation Analysis]
4 Koszalka P, Subbarao K, Baz M. Preclinical and clinical developments for combination treatment of influenza. PLoS Pathog 2022;18:e1010481. [PMID: 35551301 DOI: 10.1371/journal.ppat.1010481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 O'Driscoll LS, Martin-Loeches I. Management of Severe Influenza. Semin Respir Crit Care Med 2021;42:771-87. [PMID: 34918320 DOI: 10.1055/s-0041-1735491] [Reference Citation Analysis]
6 Ison MG, Hayden FG, Hay AJ, Gubareva LV, Govorkova EA, Takashita E, McKimm-Breschkin JL. Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Res 2021;194:105158. [PMID: 34363859 DOI: 10.1016/j.antiviral.2021.105158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]